Central Nervous System Lymphoma Clinical Trials in Hangzhou, Zhejiang
2 recruitingHangzhou, Zhejiang, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
SintilimabCentral Nervous System LymphomaPirtobrutinib
Zhejiang Cancer Hospital24 enrolled1 locationNCT07416890
Recruiting
Not Applicable
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Primary Central Nervous System Lymphoma
Zhejiang Cancer Hospital44 enrolled1 locationNCT06832267